Preclinical optimisation of intrauterine transplantation of fetal mesenchymal stem cells for osteogenesis imperfecta.

胎儿间充质干细胞宫内移植治疗成骨不全症的临床前优化。

• 批准号: nhmrc : 631641
• 负责人: A/Pr Allison Pettit
• 金额: $ 40.07万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/preclinical-optimisation-intrauterine-osteogenesis-imperfecta/82286
• 关键词: Preclinical; optimisation; intrauterine; transplantation; fetal

Osteogenesis imperfecta is a genetic disorder causing brittle bones and fractures. Currently there is no good treatment. Transplanting stem cells before birth should allow them to build healthy bones early in life. Despite promising effects in animals, stem cell uptake is too low to prevent all fractures and ameliorate pain and deformity. We are studying how to improve the uptake of stem cells given to the fetus and neonate, in order to develop a treatment suitable for eventual use in humans.

成骨不全症是一种导致骨骼脆弱和骨折的遗传性疾病。目前尚无好的治疗方法。在出生前移植干细胞应该可以让他们在生命早期就形成健康的骨骼。尽管在动物中具有良好的效果，但干细胞的摄取量太低，无法预防所有骨折并减轻疼痛和畸形。我们正在研究如何提高胎儿和新生儿对干细胞的吸收，以便开发出适合人类最终使用的治疗方法。